Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, Latin America, Europe, the United States, and internationally. The company provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system (CNS), dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It also offers Crofelemer, an anti-diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti-retro viral therapy. The company’s products under development include GRC 17536, which has completed Phase IIa of clinical trials for neuropathic pain and respiratory disorders; GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial; Vatelizumab (GBR 500) that is in Phase IIb study for multiple sclerosis; GBR 830, an anti-OX40 monoclonal antibody, that has completed Phase I clinical trials for autoimmune disorders; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 1302, a bispecific antibody, which has completed its preclinical trials for the treatment of breast and other cancers. The company was founded in 1977 and is headquartered in Mumbai, India.



Relevant Industries / Keywords

No information added

Business types

No information added

Company website
http://www.glenmarkpharma.com Employees
Number of Employees 18

This company doesn't have any public Opportunities